Hexaghen FastSorb tablets are designed to be dissolved under your tongue. Heaghen should be taken 30 minutes before bedtime. Place 2 Hexaghen FastSorb tablets under your tongue and let dissolve completely, then swallow. Do not exceed 2 tablets per day. 6 week cycle instructions: 2 weeks on (14 days), 1 week off (7 days), 2 weeks on (14 days), 1 week off (7 days), Then Repeat Cycle.
Not for use by individuals under the age of 18 years. Do not use if pregnant or nursing. Consult a physician or licensed qualified health care professional before using this product. Do not exceed recommended serving. Discontinue use and call a physician or licenses qualified health care professional immediately if you experience any adverse effects. To report any adverse even call 1-800-332-1088. Keep out of reach of children.
The relationship within the endocrine/IGF-1 axis is a complex system. Scientists have recently identified other factors that play a critical role in affecting IGF-1 levels. Approximately 98% of IGF-1 is bound to one of several insulin-like growth factor binding proteins (IGFBP). IGFBP-3, the most abundant protein, accounts for 80% of all IGF-1 binding. Research has demonstrated that reducing IGF-1 binding proteins and maintaining higher levels of free IGF-1 is correlated to improved anabolic effects and muscle development.
As reported in independent research journals, thyroid function is also associated with enhancing IGF-1 bio-active tissue levels and further increasing the rate of protein synthesis. Therefore, as IGF-1 levels are increased, a series of negative feedback controls involving the thyroid endocrine axis are triggered to keep IGF-1 levels within a narrow physiological range; not too high and not too low. By examining the relationships between GH, IGF-1 production, IGF-1 levels, free IGF-1, IGFBP and thyroid function, MuscleMeds researchers addressed this correlation between IGF-1 production and bio-effectiveness related to thyroid stimulation. HEXAGHEN’s synergistic thyroid
Research and Development
The muscle building effects of IGF-1 have been well known and medically documented for years. But the controlling factors regulating the body’s natural output have challenged researchers. Synthetic IGF-1 has been produced by major biotech pharmaceutical companies on a large scale using recombinant DNA technology. These synthetic forms must be administered via injection dosing. The development of an orally effective IGF-1 enhancing compound has long been a major global objective of biotechnologists.
After years of extensive research and laboratory analysis, MuscleMeds researchers discovered a unique IGF-1 stimulating hexapeptide (GHRP-2 Hexapeptide Acetate). Due to its long hexapeptide structure, the development of an effective oral dosage form for GHRP-2 hexapeptide posed some biotechnical challenges. Conventional oral dosing (such as tablets, capsules, liquids and softgels) was ineffective due to the gastrointestinal destruction of the GHRP-2 hexapeptide. As with other peptide substances, GHRP-2 hexapetide is subject to destruction (breakdown) in the gastrointestinal system, which eliminates the effectiveness and ability to reach the hypothalamus-pituitary axis. In order to create a product that is suitable for oral administration of the HEXAGHEN GHRP-2 Hexapeptide Acetate, MuscleMeds scientists employed the utilization of their proprietary FastSorb delivery system technology.
As a result of this researched based product development effort, HEXAGHEN features a unique IGF-1 Optimizing Complex. HEXAGHEN’s novel ingredient composition and proprietary liposomal delivery system is designed to stabilize the bioactives for rapid and high levels of absorption directly into the blood stream primarily through buccal cavity (mouth) absorption. Oral mucosal dosage delivery (transmucosally) is an alternative method of systemic nutrient delivery, which offers several advantages as the oral mucosa is highly vascularised with absorptive abilities. Therefore, HEXAGHEN’s active compounds are absorbed through the oral mucosa and directly enter the bloodstream, bypassing the gastrointestinal tract and first-pass metabolism in the liver. This improves the bioeffectiveness of delivery into the body, to trigger a series of endocrine medicated events: HEXAGHEN stimulates GH and IGF-1 levels and supports thyroid function for maximum effects.
Muscle tissue has an abundance of IGF-1 receptors. When serum IGF-1 binds to these receptor sites on muscle tissue, it stimulates the following anabolic actions and growth processes in humans, including increasing the number and size of muscle cells: